American Academy

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 24, 2023
Migraine, IPO, SG, Pharmacy, Marketing, Bank statement, AAN, IMPL, Headache (journal), AHS, Prescription, American Academy, GAAP, DHE, R, The Journal of Headache and Pain, Journal, Patient, Administration, Manuscript, Host, Otorhinolaryngology, Webcast, Growth, Research and development, American Academy of Neurology, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Safety, Video game, Cryptocurrency, Pharmaceutical industry, Health insurance, Headache, Dihydroergotamine, Pain, Q4, Impeller

SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Key Points: 
  • ET
    SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  • New Trudhesa prescriptions increased by 24 percent from Q3 to Q4 2022 driven by an expanded, more efficient salesforce.
  • Reimbursement of all shipments is 60 percent for the fourth quarter 2022.
  • ET today to discuss the fourth quarter and full year 2022 financial results and provide a corporate and business update.

RedDrop Announces Bold Stance to Support Early Menstruating Girls in Florida with $15M Donation In Services

Retrieved on: 
Thursday, March 23, 2023
United States census, Puberty, Pediatrics (journal), Body image, Walter Reddrop, Health, Woman, American Academy, Education, Female, Legislation, Toy, Nursing

ATLANTA, March 23, 2023 /PRNewswire/ -- In response to FL HB1069, RedDrop, is offering support to young girls experiencing puberty through education, services and product donations. The Atlanta-based feminine hygiene & education brand designed to empower tweens, is offering access to an online series at no cost. The estimated value of services and support is $15M to any youth participants. The move comes on the heels of the pending bill, which may hamper a tween's right to discuss her period with teachers and school staff.

Key Points: 
  • The Atlanta-based feminine hygiene & education brand designed to empower tweens, is offering access to an online series at no cost.
  • The estimated value of services and support is $15M to any youth participants.
  • With comprehensive support, RedDrop also asserts that the benefit to young girls experiencing puberty includes improved body image and a better understanding of female body functionality.
  • RedDrop encourages concerned Florida constituents to contact local legislators, including members of the Education Quality Subcommittee, to express their support for the health, wellness and education of tweens.

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Emory University School of Medicine, APRIL, Cold agglutinin disease, Dermatology, Kidney, American Academy, Immunoglobulin A, Lupus, Publication, Investment, Dialysis, Transplant, IgA nephropathy, Hospital, Medical director, MD, AbbVie, ALPN, Patient, Lupus nephritis, Webcast, BAFF, Cytokine, Horizon, Autoimmunity, Inflammation, Glomerulonephritis, Pharmaceutical industry, Gemstone, Nursing, Cryptocurrency, Alpine, Medicine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.
  • Collaboration revenue for the quarter ended December 31, 2022 was $2.8 million compared to $4.5 million for the quarter ended December 31, 2021.
  • Research and development expenses for the quarter ended December 31, 2022 were $18.8 million compared to $15.4 million for the quarter ended December 31, 2021.
  • The Company recorded net losses of $18.9 million and $15.2 million for the quarters ended December 31, 2022 and 2021, respectively.

MetLife Names Bryan Boudreau New Global Chief Actuary

Retrieved on: 
Thursday, March 23, 2023
Professional Services, Finance, Morgan Stanley, Uncertainty, Society, Reward, American Academy, History, NYSE, Aon Hewitt, Barclays, American Academy of Actuaries, Society of Actuaries, MET, MetLife, MetLife Inc. v. Financial Stability Oversight Council, New York Life Insurance Company, Life insurance

MetLife, Inc. (NYSE: MET) today announced that Bryan Boudreau has been named executive vice president and Global Chief Actuary, effective May 11, 2023.

Key Points: 
  • MetLife, Inc. (NYSE: MET) today announced that Bryan Boudreau has been named executive vice president and Global Chief Actuary, effective May 11, 2023.
  • In this role, Boudreau will lead a global team that uses valuations, experience studies, pricing, modeling, asset and liability management and other actuarial functions to ensure MetLife meets its obligations to customers and shareholders.
  • Boudreau succeeds Andy Rallis, who will retire effective May 10, 2023, after a 39-year career at MetLife – including 11 years as Global Chief Actuary.
  • Prior to MetLife, Boudreau held leadership and advisory positions at New York Life Insurance Company, Mercer Investments, Morgan Stanley, and Barclays Capital.

PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, March 23, 2023
PGN, Heart, GLP, Myogenesis, Duchenne muscular dystrophy, Therapy, DM1, Muscular dystrophy, RCT, Clinical trial, SAD, American Academy, Research, Cell, CUG, Research and development, Development, CTG, DMD, Patient, EDO, Physician, Episcopal conference, Administration, DMPK, MAD, NHP, HV, American Academy of Neurology, IND, Conference, Caregiver, Disease, Pharmaceutical industry, Cryptocurrency, Neurology

In December 2022, PepGen announced IND-enabling preclinical data supporting the progression of PGN-EDODM1 for the treatment of DM1 into clinical studies.

Key Points: 
  • In December 2022, PepGen announced IND-enabling preclinical data supporting the progression of PGN-EDODM1 for the treatment of DM1 into clinical studies.
  • Net loss was $14.9 million for the three months ended December 31, 2022, compared to $7.1 million for the same period in 2021.
  • Net loss was $69.1 million for the year ended December 31, 2022, compared to $27.3 million for the same period in 2021.
  • PepGen had approximately 23.7 million shares outstanding on December 31, 2022

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
ACAAI, PD, Allergy, Emergency, Investment, ARS, New Drug Application, European Medicines Agency, Clinical trial, NDA, Pharmacokinetics, American Academy, G&A, American Academy of Allergy, Asthma, and Immunology, Marketing, EMA, Pain, Asthma, Patient, Nature, Adrenaline, Rhinitis, SAN, OTC, PDUFA, AAAAI, R, MAA, Research, Caregiver, FDA, American College, Regulation of tobacco by the U.S. Food and Drug Administration, Treatment, Food, American College of Allergy, Asthma and Immunology, D, Vaccine, Pharmaceutical industry, Anaphylaxis

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported fourth quarter and full year 2022 financial results.

Key Points: 
  • We believe we are well on our way to achieving this goal,” said Richard Lowenthal, president and chief executive officer of ARS Pharmaceuticals.
  • R&D Expenses: Research and development (R&D) expenses were $4.7 million for the quarter ended December 31, 2022, and $18.4 million for the year ended December 31, 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $10.7 million for the quarter ended December 31, 2022, and $18.5 million for the year ended December 31, 2022.
  • Net Loss: Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO RELIEVE ITCHY PSORIASIS

Retrieved on: 
Thursday, March 23, 2023
Infection, Hair, American Academy of Dermatology, Diabetes, Eastern Virginia Medical School, Sleep, Cardiovascular disease, Nail, Psoriasis, Quality of life, American Academy, FAAD, Scalp, Patient, AAD, Risk, Water, Bath, Joint, Diagnosis, Itch, Health, Menthol, Skin, Medical device, Cosmetics

ROSEMONT, Ill., March 23, 2023 /PRNewswire/ -- Skin issues can have a serious impact on your health and well-being. For the 7.5 million Americans1 living with psoriasis, itch can be the most bothersome part of their condition because it can make it difficult to sleep and hard to concentrate, as well as affect other aspects of their quality of life. To help relieve your psoriasis itch, a board-certified dermatologist from the American Academy of Dermatology (AAD) is providing four important tips to consider.

Key Points: 
  • To help relieve your psoriasis itch, a board-certified dermatologist from the American Academy of Dermatology (AAD) is providing four important tips to consider.
  • "That's why it's so important to know how to relieve your itch so this doesn't happen."
  • To ease itch caused by your psoriasis, Dr. Pariser and the AAD recommend these tips:
    Limit time in water to avoid drying your skin.
  • These tips are demonstrated in " How to Relieve Itchy Psoriasis ," a video posted to the AAD website and YouTube channel .

New evidence demonstrates Smith+Nephew's COBLATION™ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques

Retrieved on: 
Thursday, March 23, 2023
Contraindication, Sleep apnea, American Academy of Otolaryngology–Head and Neck Surgery, LSE, Tonsillectomy, Surgeon, Diet, Use, Directory of Open Access Journals, Open access, CIT, American Academy, Research, Temperature, Meta-analysis, PTH, Blood, Otorhinolaryngology, Pain, Literature, Patient, SNN, NYSE, Pharmaceutical industry

COBLATION Intracapsular Tonsillectomy involves the removal of all, or the majority, of tonsil tissue while maintaining the integrity of the underlying capsule.

Key Points: 
  • COBLATION Intracapsular Tonsillectomy involves the removal of all, or the majority, of tonsil tissue while maintaining the integrity of the underlying capsule.
  • Intracapsular Tonsillectomy is growing in popularity with 20% of paediatric otolaryngologists performing this procedure in the US.2
    For more information about COBLATION Intracapsular Tonsillectomy, please visit https://www.smith-nephew.com/en/health-care-professionals/products/ear-n...
    1.
  • Sedgwick MJ, Saunders C, Bateman N. Intracapsular tonsillectomy using plasma ablation versus total tonsillectomy: a systematic literature review and meta-analysis.
  • Post Tonsillectomy Haemorrhage (PTH) is a potentially serious complication that has been reported in literature for both adult and paediatric patients.

New evidence demonstrates Smith+Nephew's COBLATION™ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques

Retrieved on: 
Thursday, March 23, 2023
Contraindication, Sleep apnea, American Academy of Otolaryngology–Head and Neck Surgery, LSE, Tonsillectomy, Surgeon, Diet, Use, Directory of Open Access Journals, Open access, CIT, American Academy, Research, Temperature, Meta-analysis, PTH, Blood, Otorhinolaryngology, Pain, Literature, Patient, SNN, NYSE, Pharmaceutical industry

COBLATION Intracapsular Tonsillectomy involves the removal of all, or the majority, of tonsil tissue while maintaining the integrity of the underlying capsule.

Key Points: 
  • COBLATION Intracapsular Tonsillectomy involves the removal of all, or the majority, of tonsil tissue while maintaining the integrity of the underlying capsule.
  • Intracapsular Tonsillectomy is growing in popularity with 20% of paediatric otolaryngologists performing this procedure in the US.2
    For more information about COBLATION Intracapsular Tonsillectomy, please visit https://www.smith-nephew.com/en/health-care-professionals/products/ear-n...
    1.
  • Sedgwick MJ, Saunders C, Bateman N. Intracapsular tonsillectomy using plasma ablation versus total tonsillectomy: a systematic literature review and meta-analysis.
  • Post Tonsillectomy Haemorrhage (PTH) is a potentially serious complication that has been reported in literature for both adult and paediatric patients.

Panacea Healthcare Solutions Hosting Webinar on Interventional Cardiology Code Set Updates

Retrieved on: 
Wednesday, March 22, 2023
Documentation, Education, Q&A, Health, CEU, CPT, Professional association, Current Procedural Terminology, American Academy, EST, AAPC, Medicine, Project Management Institute, Patient, Physician, Continuing education unit, National Library and Documentation Services Board, TAVR, Panacea, Growth, Emerging technologies, Aortic stenosis, PMI, Hospital, Medical device, Auction

ST. PAUL, Minn., March 22, 2023 /PRNewswire-PRWeb/ -- Panacea Healthcare Solutions, a leading provider of strategic pricing, price transparency, chargemaster, compliance, and revenue integrity software, education, and consulting services to healthcare providers across the full continuum of care, is hosting a newly developed webinar intended to help healthcare professionals keep up with recent advances in novel treatment options in the subspecialty of interventional cardiology.

Key Points: 
  • Panacea Healthcare Solutions, a leading provider of strategic pricing, price transparency, chargemaster, compliance, and revenue integrity software, education, and consulting services to healthcare providers across the full continuum of care, is hosting a newly developed webinar intended to help healthcare professionals keep up with recent advances in novel treatment options in the subspecialty of interventional cardiology.
  • ST. PAUL, Minn., March 22, 2023 /PRNewswire-PRWeb/ -- Panacea Healthcare Solutions, a leading provider of strategic pricing, price transparency, chargemaster, compliance, and revenue integrity software, education, and consulting services to healthcare providers across the full continuum of care, is hosting a newly developed webinar intended to help healthcare professionals keep up with recent advances in novel treatment options in the subspecialty of interventional cardiology.
  • The Current Procedural Terminology (CPT) transcatheter valvular procedure code set has significantly expanded since the transcatheter aortic valve replacement (TAVR) codes were created in 2013, with new procedures for all four cardiac valves added in several areas of the code book.
  • "The material being covered will undoubtedly prove invaluable to the success and growth of any transcatheter structural heart program."